Published in Br J Haematol on October 01, 2007
Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma. Korean J Hematol (2011) 0.77
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med (2005) 4.96
Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A (2010) 2.86
Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol (2008) 2.70
Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol (2010) 2.60
Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica (2002) 2.34
A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science (2009) 2.30
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol (2009) 2.10
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res (2009) 2.01
Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay. Neuroradiology (2008) 1.96
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol (2007) 1.94
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol (2008) 1.64
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. Br J Haematol (2008) 1.58
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res (2006) 1.52
Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. J Immunol (2003) 1.52
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. Cancer Genet Cytogenet (2010) 1.51
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica (2002) 1.47
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. Br J Haematol (2005) 1.45
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia. Blood (2010) 1.43
Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. Leuk Res (2013) 1.42
Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol (2007) 1.41
Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood (2006) 1.38
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma (2014) 1.37
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood (2009) 1.36
Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain (2008) 1.36
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood (2011) 1.35
Recombinant C1 inhibitor in brain ischemic injury. Ann Neurol (2009) 1.33
Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol (2005) 1.26
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol (2009) 1.25
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol (2011) 1.24
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood (2012) 1.23
Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res (2004) 1.21
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res (2009) 1.21
Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. J Immunol (2004) 1.19
An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo. J Biol Chem (2013) 1.18
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer (2011) 1.18
On-chip manipulation of protein-coated magnetic beads via domain-wall conduits. Adv Mater (2010) 1.14
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. Br J Haematol (2008) 1.12
The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood (2007) 1.12
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. Br J Haematol (2008) 1.12
Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Biochemistry (2010) 1.11
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol (2003) 1.09
Gene therapy in epilepsy: the focus on NPY. Peptides (2006) 1.04
Misplaced NMDA receptors in epileptogenesis contribute to excitotoxicity. Neurobiol Dis (2011) 1.04
Antiepileptic effects of botulinum neurotoxin E. J Neurosci (2005) 1.03
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.03
Multiple myeloma involving the cavernous sinus: a report of 3 cases and response to bortezomib. Clin Lymphoma Myeloma (2007) 1.03
Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation (2012) 1.03
CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood (2002) 1.02
The antidepressant mechanism of Hypericum perforatum. Life Sci (2004) 1.01
Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. PLoS One (2011) 1.00
Insights into JAK2-V617F mutation in CML. Lancet Oncol (2007) 0.99
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. Br J Haematol (2008) 0.98
Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol (2006) 0.98
Consecutive regression of concurrent laryngeal and gastric MALT lymphoma after anti-Helicobacter pylori therapy. Gastroenterology (2003) 0.98
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood (2002) 0.97
Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst (2007) 0.97
Specific recognition of biologically active amyloid-β oligomers by a new surface plasmon resonance-based immunoassay and an in vivo assay in Caenorhabditis elegans. J Biol Chem (2012) 0.97
The GTPase-activating protein RN-tre controls focal adhesion turnover and cell migration. Curr Biol (2013) 0.97
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol (2004) 0.97
High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood (2011) 0.97
Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood (2006) 0.96
Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group. Haematologica (2010) 0.96
Mutant PrP suppresses glutamatergic neurotransmission in cerebellar granule neurons by impairing membrane delivery of VGCC α(2)δ-1 Subunit. Neuron (2012) 0.96
A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Leuk Lymphoma (2005) 0.95
WB4101-related compounds: new, subtype-selective alpha1-adrenoreceptor antagonists (or inverse agonists?). J Med Chem (2006) 0.95
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des (2013) 0.95
Conformational plasticity of the Gerstmann-Sträussler-Scheinker disease peptide as indicated by its multiple aggregation pathways. J Mol Biol (2008) 0.95
Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements. Genes Chromosomes Cancer (2004) 0.94
Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem (2010) 0.94
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. Am J Hematol (2014) 0.93
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes Cancer (2011) 0.93
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. Blood (2013) 0.93
Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials (2010) 0.92
Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials. Clin Lymphoma Myeloma Leuk (2010) 0.92
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. Haematologica (2008) 0.91
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma (2011) 0.91
Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. Blood (2004) 0.91
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma (2011) 0.91
Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer's disease. ACS Nano (2012) 0.91
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases. Eur J Haematol (2008) 0.91
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PLoS One (2011) 0.90
Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica (2006) 0.90
Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment. Acta Haematol (2007) 0.89